



**THE FOUNDATION
FOR SECURE
MARKETS®**

#56935

Date: July 23, 2025

Subject: Akoya Biosciences, Inc. – Cash In Lieu Settlement
Adjusted Option Symbol: QTRX1

Akoya Biosciences, Inc. options were adjusted on July 8, 2025 (See OCC Information Memo #56881). The new deliverable became 1) 14 Quanterix Corporation (QTRX) Common Shares, 2) Cash in lieu of 0.7 fractional QTRX shares, and 3) \$37.00 Cash. Only settlement of the cash portion of QTRX1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of \$6.6591 per whole QTRX share will be used to determine the cash in lieu amount. Accordingly, the cash in lieu amount is:

$$0.7 \times \$6.6591 = \$4.66 \text{ per QTRX1 Contract}$$

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of July 8, 2025 through July 23, 2025, to deliver the appropriate cash amount.

The cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

Terms of the QTRX1 options are as follows:

New Deliverable

Per Contract: 1) 14 Quanterix Corporation (QTRX) Common Shares
2) \$41.66 Cash (\$37.00 + \$4.66)

Strike Prices: Unchanged

CUSIP: QTRX: 74766Q101

Multiplier: 100 (i.e., a premium of 1.50 yields \$150)

Settlement

The QTRX component of QTRX1 exercise/assignment activity from July 8, 2025 through July 22, 2025, has settled through National Security Clearing Corporation (NSCC). The \$41.66 cash amount will be settled by OCC.

Pricing

The underlying price for QTRX1 will be determined as follows:

$$\text{QTRX1} = 0.14 (\text{QTRX}) + 0.4166$$

For example, if QTRX closes at 5.51, the QTRX1 price would be calculated as follows:

$$\text{QTRX1} = 0.14 (5.51) + 0.4166 = 1.19$$

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.